In order to evaluate the dynamics of fitness of HSPCs in terms of their ability to form colonies, we isolated and studied CD34+ cells from the bone marrow of a patient with IDH2-R140Q-mutated AML, and we had the opportunity to follow under treatment with enasidenib. Here, IDH2 is linked to acute myeloid leukemia.